Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Oncology

Prevalence

8.0 / 100K

Incidence

1.8 / 100K/yr

2 drugs in development·1 company·1 clinical trial

Drug Pipeline by Phase

Phase 1(1)
DrugCompany
blinatumomabAMGEN INC (AMGN)

Compare drugs

low-intensity chemotherapy regimen vs blinatumomab

Frequently asked questions

How many drugs are in development for Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)?

BioSniper tracks 2 drugs in development for Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) across 1 company.

How many clinical trials target Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)?

There are 1 clinical trial targeting Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) tracked by BioSniper.

What is the prevalence of Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)?

The estimated prevalence of Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) is approximately 8.0 per 100,000 population.

Deep-dive into Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) — Drugs in Development & Clinical Trials | BioSniper